India, May 2 -- image credit- shutterstock

Remidio Innovative Solutions has received approval from the State FDA, Karnataka (CDSCO), the regulatory authority for medical devices, for its Medios HI (Humanising Intelligence) Glaucoma AI and Medios HI AMD AI.

This approval represents an important advancement in the use of artificial intelligence (AI) for early detection of glaucoma and age-related macular degeneration (AMD) in diverse healthcare settings.

Following the success of the CDSCO-approved Medios DR HI, AI for diabetic retinopathy, which has impacted nearly 2,50,000 patients in the past year, the newly approved AI solutions for glaucoma and AMD are also designed to function offline. This offline capability allows real-time analys...